GlucoTrack closes $10M public offering of common stock and pre-funded warrants

Glucotrack, Inc.

Gross proceeds of ~$10.0M from firm commitment offering; 7,352,942 shares and pre-funded warrants sold at $1.36/unit.
Underwriting agreement signed April 13, 2023; Aegis Capital Corp. acted as sole book-running manager.
Net proceeds allocated to working capital, general corporate purposes, including potential acquisitions and sales/marketing.
Offering conducted under effective S-3 shelf registration (No. 333-259664); prospectus supplement filed with SEC.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Glucotrack, Inc. entered into a underwriting with Aegis Capital Corp. valued at approximately $10.0 million (effective 2023-04-13).

Action: entry
Agreement: underwriting
Counterparty: Aegis Capital Corp.
Value: approximately $10.0 million
Effective: 2023-04-13

Exact text from the filing

ompany entered into an underwriting agreement with Aegis Capital Corp. on April 13, 2023. The Company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, which may include,

View on SEC.gov

15 material agreements filed in the last 30 days. Browse all material agreements →

Glucotrack, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-012431

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.